US 7220745
Heterocyclic compounds useful to treat HCV
granted A61PA61P31/12
Quick answer
US patent 7220745 (Heterocyclic compounds useful to treat HCV) held by Rigel Pharmaceuticals, Inc. expires Mon May 17 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue May 22 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 17 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61P, A61P31/12